



**Clinical Laserthermia Systems to Exhibit at DMI's
"Prostate MRI and MR-Guided Intervention in the Desert"**
Continuing Medical Education Event Hosted by Desert Medical Imaging

Palm Springs, CA – September 26, 2018 - [Clinical Laserthermia Systems Americas, Inc.](#) (CLS Americas) a subsidiary of CLS AB in Lund, Sweden, today announced it will be exhibiting and presenting at the upcoming Continuing Medical Education (CME), 3-day event, ["Prostate MRI and MR-Guided Intervention in the Desert"](#) this coming October 18-20, 2018 in Palm Springs, CA.

The CME Accredited event is being hosted and organized by Desert Medical Imaging and will be held at the USCAP Interactive Learning Center in Palm Springs, California. Conference participants will learn the latest advancements in multi-parametric prostate MRI, MRI-guided interventions and genitourinary pathology from a group of leading physician experts from around the world. For more information on the event, visit: www.desertmedicalimaging.com/CME or call 760-766-2047.

"Desert Medical Imaging is pleased to have Clinical Laserthermia Systems as an exhibitor and participant in this CME conference that will include prostate MRI, MRI-guided biopsy and results of a clinical trial involving MRI-guided laser ablation of prostate cancer," stated Bernadette M. Greenwood, BSc, PG Cert., RT(R)(MR)(ARRT), chief research officer Desert Medical Imaging, clinical instructor, UC Riverside School of Medicine.

"Desert Medical Imaging is a pioneer and visionary in the advanced, minimally-invasive treatment of prostate cancer utilizing MRI-guided focal laser ablation therapy," stated Alan Weinberg, General Manager for CLS Americas, Inc. "We are pleased and excited to participate in this important event as it demonstrates our relevance and commitment to this growing area of interest area in the field of urology."

In the United States alone, new prostate cancer cases for 2017 were estimated at 161,360 and deaths at 26,730 according to the AACR. Focal therapies for low risk and intermediate risk localized prostate cancer are increasingly being explored.

About the CLS TRANBERG® | Thermal Therapy System

CLS developed the system for image guided high precision soft tissue thermal therapy and ablation procedures. The system can be configured for MR or CT/US-guided procedures using tissue temperature feedback for precise therapy and ablation control. The system includes a desktop mobile

laser unit, new innovative non-cooled laser applicators, external tissue temperature probe sensors and procedure specific accessories.

About Clinical Laserthermia Systems

Clinical Laserthermia Systems AB (publ), develops and sells the TRANBERG® | Thermal Therapy System and specially-designed sterile disposable products for safe, gentle and effective treatment of cancerous tumors. The products are marketed for image-guided laser ablation and for treatment with immuno-stimulating interstitial laser thermotherapy, imILT®. The company, which is headquartered in Lund Sweden and has a subsidiary in Boston, MA, is listed Nasdaq First North under the ticker CLS B. Certified Adviser is Västra Hamnen Corporate Finance. Further information is available on www.clinicallaser.se.

###

The TRANBERG® | Thermal Therapy System has not yet received market clearance for immune stimulating interstitial laser thermotherapy (imILT®) by the Food and Drug Administration (FDA) in the United States of America (USA).

Media Contact

TopSpin Communications
Joe Waldygo
P: 480-363-8774
E: joe@topspinpr.com

Company Contact

CLS Americas, Inc.
Alan Weinberg, General Manager
P: 508-620-4521
E: alan@clinicallaser.se